Evidence map›Paper›PMID 37108120›Full record

ArticleInternational journal of molecular sciences2023

Untargeted Lipidomic Profiling Reveals Lysophosphatidylcholine and Ceramide as Atherosclerotic Risk Factors in

Shi-Hui Law, Hua-Chen Chan, Guan-Ming Ke, Swetha Kamatam, Gopal Kedihithlu Marathe, Vinoth Kumar Ponnusamy, Liang-Yin Ke

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 19 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Shi-Hui LawDepartment of Medical Laboratory Science and Biotechnology, College of Health Sciences, Kaohsiung Medical University, Kaohsiung 80708, Taiwan.
Hua-Chen ChanDepartment of Medical Laboratory Science, College of Medicine, I-Shou University, Kaohsiung 84001, Taiwan.ORCID 0000-0001-7016-8392
Guan-Ming KeGraduate Institute of Animal Vaccine Technology, College of Veterinary Medicine, National Pingtung University of Science and Technology, Pingtung 91201, Taiwan.
Swetha KamatamDepartment of Studies in Biochemistry and Molecular Biology, University of Mysore, Manasagangothri, Mysuru 570006, India.
Gopal Kedihithlu MaratheDepartment of Studies in Biochemistry and Molecular Biology, University of Mysore, Manasagangothri, Mysuru 570006, India.
Vinoth Kumar PonnusamyDepartment of Medicinal and Applied Chemistry, Research Center for Precision Environmental Medicine, Kaohsiung Medical University, Kaohsiung 80708, Taiwan.ORCID 0000-0003-2112-2085
Liang-Yin KeDepartment of Medical Laboratory Science and Biotechnology, College of Health Sciences, Kaohsiung Medical University, Kaohsiung 80708, Taiwan.ORCID 0000-0002-2547-0987
Kaohsiung Medical University · TWUniversity of Mysore · INNational Pingtung University of Science and Technology · TW

Funding

Kaohsiung Medical University KMU-DK(A)111002Taiwan Ministry of Science and Technology NSTC-111-2320-B-037-023-, NSTC-111-2628-B-214-002-
6 · The paper itself

Abstract

Despite the availability and use of numerous cholesterol-lowering drugs, atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of mortality globally. Many researchers have focused their effort on identifying modified lipoproteins. However, lipid moieties such as lysophosphatidylcholine (LPC) and ceramide (CER) contribute to atherogenic events. LPC and CER both cause endothelial mitochondrial dysfunction, leading to fatty acid and triglyceride (TG) accumulation. In addition, they cause immune cells to differentiate into proinflammatory phenotypes. To uncover alternative therapeutic approaches other than cholesterol- and TG-lowering medications, we conducted untargeted lipidomic investigations to assess the alteration of lipid profiles in

Indexed as

AtherosclerosisLysophosphatidylcholinesAnimalsApolipoproteinsApolipoproteins ECeramidesCholesterolLipidomicsMiceMice, Inbred C57BLMice, KnockoutRisk FactorsTriglyceridesApolipoproteinsApolipoproteins ECeramidesCholesterolLysophosphatidylcholinesTriglyceridesapolipoprotein E (apoE) knockoutatherosclerosisatherosclerotic cardiovascular disease (ASCVD)ceramide (CER)cholesteryl ester (CE)lipidomiclysophosphatidylcholine (LPC)mass spectrometrytriglyceride (TG)

Identifiers

PMID37108120
PMCPMC10138920
OpenAlexW4363679362

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.